Zipalertinib Extends PFS in REZILIENT3
Zipalertinib plus platinum chemotherapy reduced the risk of progression or death by 50% versus chemotherapy alone in first-line EGFR exon 20 insertion-positive advanced NSCLC. Median PFS improved from 8.5 to 14.5 months and response…
